Search Result

Results for "

human+carboxylesterase+1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (6) Autophagy (2) Bacterial (2) Bcl-2 Family (2) Calcium Channel (1) Carboxylesterase (CES) (3) DNA/RNA Synthesis (2) GLP Receptor (2) HDAC (2) Insulin Receptor (2) Isotope-Labeled Compounds (2) p38 MAPK (2) Reactive Oxygen Species (ROS) (1) Reference Standards (2) α-synuclein (2)
By Research Areas:	Cancer (6) Endocrinology (2) Infection (2) Inflammation/Immunology (2) Metabolic Disease (6) Neurological Disease (2)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-134124

Glutathione ethyl ester	Reactive Oxygen Species (ROS)	Metabolic Disease
Glutathione ethyl ester is a cell-permeable GSH donor and provides an efficient supply of GSH to the oocyte. Glutathione ethyl ester shows positive effect on the in vitro production of embryos by enhancement of the antioxidative defense ^[1].

HY-N1377

Nevadensin Lysionotin	Carboxylesterase (CES) DNA/RNA Synthesis Apoptosis Bacterial	Infection Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Nevadensin (Lysionotin), a natural flavonoid, is a selective **human carboxylesterase 1 (hCE1) inhibitor with an IC₅₀ of 2.64 μM. Nevadensin is more selective for hCE1 than hCE2 (IC₅₀ of 132.8 μM). Nevadensin can induce apoptosis and DNA damage** in cancer cells. Nevadensin has a variety of pharmacological effects such as anti-inflammatory, anti-tumour, anti-hypertensive, anti-tubercular, antitussive, antioxidant and anti-microbial activities ^[1] .

HY-114118S1

Semaglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer ^[1] .

HY-114118S

Semaglutide-d8	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer ^[1] .

HY-144809

*Pancreatic lipase/Carboxylesterase* 1-IN-1**	Carboxylesterase (CES)	Metabolic Disease
Pancreatic lipase/Carboxylesterase 1-IN-1 (Compound 39) is a potent dual inhibitor of pancreatic lipase (PL) and **human carboxylesterase 1A (hCES1A) with IC₅₀** values of 2.13 µM and 0.055 µM against PL and hCES1A ^[1].

HY-106409

Tefinostat 1 Publications Verification CHR-2845	HDAC Apoptosis	Cancer
Tefinostat (CHR-2845) is a monocyte/macrophage targeted histone deacetylase (HDAC) inhibitor. Tefinostat can be cleaved into active acid CHR-2847 by the intracellular esterase human carboxylesterase-1 (hCE-1). Tefinostat can be used for the research of leukaemias ^[1].

HY-P2424

Cholecystokinin-J CCK-J	Calcium Channel	Others
Cholecystokinin-J (CCK-J), a cholecystokinin, stimulates Ca ²⁺ release ^[1].

HY-N1377R

Nevadensin (Standard) Lysionotin (Standard)	Carboxylesterase (CES) Reference Standards DNA/RNA Synthesis Apoptosis Bacterial	Infection Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Nevadensin (Standard) (Lysionotin (Standard)) is the analytical standard of Nevadensin (HY-N1377). This product is intended for research and analytical applications. Nevadensin, a natural flavonoid, is a selective **human carboxylesterase 1 (hCE1) inhibitor with an IC₅₀ of 2.64 μM. Nevadensin is more selective for hCE1 than hCE2 (IC₅₀ of 132.8 μM). Nevadensin can induce apoptosis and DNA damage** in cancer cells. Nevadensin has a variety of pharmacological effects such as anti-inflammatory, anti-tumour, anti-hypertensive, anti-tubercular, antitussive, antioxidant and anti-microbial activities.

HY-106409R

Tefinostat (Standard) CHR-2845 (Standard)	Reference Standards HDAC Apoptosis	Cancer
Tefinostat (Standard) is the analytical standard of Tefinostat (HY-106409). This product is intended for research and analytical applications. Tefinostat (CHR-2845) is a monocyte/macrophage targeted histone deacetylase (HDAC) inhibitor. Tefinostat can be cleaved into active acid CHR-2847 by the intracellular esterase human carboxylesterase-1 (hCE-1). Tefinostat can be used for the research of leukaemias ^[1].

Cat. No.	Product Name	Target	Research Area

HY-134124

Glutathione ethyl ester	Reactive Oxygen Species (ROS)	Metabolic Disease
Glutathione ethyl ester is a cell-permeable GSH donor and provides an efficient supply of GSH to the oocyte. Glutathione ethyl ester shows positive effect on the in vitro production of embryos by enhancement of the antioxidative defense ^[1].

HY-114118S1

Semaglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer ^[1] .

HY-114118S

Semaglutide-d8	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer ^[1] .

HY-P2424

Cholecystokinin-J CCK-J	Calcium Channel	Others
Cholecystokinin-J (CCK-J), a cholecystokinin, stimulates Ca ²⁺ release ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1377

Nevadensin Lysionotin	Flavonoids other families Classification of Application Fields Flavones Phenols Polyphenols Metabolic Disease Plants Inflammation/Immunology Disease Research Fields Source Classification	Carboxylesterase (CES) DNA/RNA Synthesis Apoptosis Bacterial
Nevadensin (Lysionotin), a natural flavonoid, is a selective **human carboxylesterase 1 (hCE1) inhibitor with an IC₅₀ of 2.64 μM. Nevadensin is more selective for hCE1 than hCE2 (IC₅₀ of 132.8 μM). Nevadensin can induce apoptosis and DNA damage** in cancer cells. Nevadensin has a variety of pharmacological effects such as anti-inflammatory, anti-tumour, anti-hypertensive, anti-tubercular, antitussive, antioxidant and anti-microbial activities ^[1] .

HY-N1377R

Nevadensin (Standard) Lysionotin (Standard)	Structural Classification Flavonoids other families Flavones Phenols Polyphenols Plants Source Classification	Carboxylesterase (CES) Reference Standards DNA/RNA Synthesis Apoptosis Bacterial
Nevadensin (Standard) (Lysionotin (Standard)) is the analytical standard of Nevadensin (HY-N1377). This product is intended for research and analytical applications. Nevadensin, a natural flavonoid, is a selective **human carboxylesterase 1 (hCE1) inhibitor with an IC₅₀ of 2.64 μM. Nevadensin is more selective for hCE1 than hCE2 (IC₅₀ of 132.8 μM). Nevadensin can induce apoptosis and DNA damage** in cancer cells. Nevadensin has a variety of pharmacological effects such as anti-inflammatory, anti-tumour, anti-hypertensive, anti-tubercular, antitussive, antioxidant and anti-microbial activities.

Cat. No.	Product Name	Chemical Structure

HY-114118S1

Semaglutide-d8 tetraTFA
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer ^[1] .

Semaglutide-d8 tetraTFA

Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer ^[1] .

HY-114118S

Semaglutide-d8
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer ^[1] .

Semaglutide-d8

Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer ^[1] .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

human+carboxylesterase+1

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products